Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of LY4100511 in adults with moderate-to-severe plaque psoriasis
2024-512207-39-00Phase 2Completed
- Sponsor
- DICE Therapeutics
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing LY4100511 dose-ranging arms with Placebo arm (2 arms). Primary endpoint: PASI 75 at Week 12. Started Jan 2025; status: completed.
02
Drugs
simepdekinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2024-512207-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512207-39-00.